Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...
Vertex Pharmaceuticals gets CHMP opinion recommending Kaftrio label expansion
Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
precisionmedicineonline7h
CHMP Recommends Vertex's Kaftrio, Kalydeco Combo for Additional Cystic Fibrosis Patients
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
pharmaphorum22h
Celebrations as NHS England agrees deal for Vertex’ cystic fibrosis triple
Kaftrio is the first drug that works in patients with the F508del and MF mutations, who account for around 90% of the overall CF population, and in trials led to improved lung function as well as ...
Vertex: Strong Sales, Stronger Pipeline
One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's ...
Zacks.com on MSN17d
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, missing the Zacks Consensus Estimate of $3.99. The bottom line declined 5.2% on a ...
Vertex Raises Guidance Despite Q2's Bottom-Line Losses
In the realm of gene-editing therapies, Vertex has launched Casgevy, an ex-vivo gene-edited cell therapy for the severe blood disorders sickle cell disease and transfusion-dependent beta-thalassemia.
Morningstar16d
Vertex Earnings: Strong Cash Flows From Cystic Fibrosis Franchise Help Diversify Portfolio
Strong demand for its CF therapy, Trikafta/Kaftrio, delivered $10.2 billion in revenue for the year. We appreciate that Vertex is using its healthy cash flows from its CF franchise to expand its ...